

Azathioprine

References to Supplementary Web Tables, Section 2

- Kandiel A, Fraser AG, Korelitz BI *et al.* (2005). Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. *Gut*, 54:1121–1125 [doi:10.1136/gut.2004.049460](https://doi.org/10.1136/gut.2004.049460). [PMID:16009685](https://pubmed.ncbi.nlm.nih.gov/16009685/)
- Bernatsky S, Joseph L, Boivin JF *et al.* (2008). The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. *Ann Rheum Dis*, 67:74–79 [doi:10.1136/ard.2006.069039](https://doi.org/10.1136/ard.2006.069039). [PMID:17545189](https://pubmed.ncbi.nlm.nih.gov/17545189/)
- Fraser AG, Orchard TR, Robinson EM, Jewell DP (2002). Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. *Aliment Pharmacol Ther*, 16:1225–1232 [doi:10.1046/j.1365-2036.2002.01297.x](https://doi.org/10.1046/j.1365-2036.2002.01297.x). [PMID:12144571](https://pubmed.ncbi.nlm.nih.gov/12144571/)
- Matula S, Croog V, Itzkowitz S *et al.* (2005). Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. *Clin Gastroenterol Hepatol*, 3:1015–1021 [doi:10.1016/S1542-3565\(05\)00738-X](https://doi.org/10.1016/S1542-3565(05)00738-X). [PMID:16234048](https://pubmed.ncbi.nlm.nih.gov/16234048/)